Table 1.
Characteristics of patients included in the study
| Variable | GF (N=519) |
CC+GF (N=449) |
P | |
|---|---|---|---|---|
| Age at transplant | 0.63 | |||
| median (range) | 58 (25–78) | 58 (23–74) | ||
| 18–39 | 15 (3%) | 17 (4%) | ||
| 40–49 | 80 (15%) | 70 (16%) | ||
| 50–59 | 218 (42%) | 174 (39%) | ||
| 60–69 | 182 (35%) | 172 (38%) | ||
| ≥70 | 24 (5%) | 16 (4%) | ||
| Gender | 0.78 | |||
| Male | 304 (59%) | 259 (58%) | ||
| Female | 215 (41%) | 190 (42%) | ||
| Race | 0.07 | |||
| Caucasian | 411 (79%) | 335 (75%) | ||
| African American | 89 (17%) | 86 (19%) | ||
| Others, unknown | 19 (4%) | 28 (6%) | ||
| Karnofsky score | 0.30 | |||
| ≥90 | 283 (55%) | 261 (58%) | ||
| <90 | 193 (37%) | 161 (36%) | ||
| Missing | 43 (8%) | 27 (6%) | ||
| HCT-Comorbidity Index | 0.006 | |||
| 0 | 227 (44%) | 227 (51%) | ||
| 1–2 | 147 (29%) | 134 (30%) | ||
| >2 | 145 (28%) | 88 (20%) | ||
| Isotype | 0.36 | |||
| IgG | 375 (72%) | 333 (74%) | ||
| IgA | 21 (4%) | 19 (4%) | ||
| Light chain | 101 (19%) | 82 (18%) | ||
| Others, unknown | 22 (5%) | 15 (4%) | ||
| Stage III at diagnosis* | 160 (31%) | 162 (36%) | 0.22 | |
| Number of prior therapy regimens** | <0.001 | |||
| 1 | 382 (74%) | 265 (59%) | ||
| 2 | 113 (22%) | 136 (30%) | ||
| >2 | 24 (5%) | 48 (11%) | ||
| Prior therapy regimens** | <0.001 | |||
| Thalidomide + bortezomib +- corticosteroid | 74 (14%) | 92 (20%) | ||
| Lenalidomide+ bortezomib +- corticosteroid | 121 (23%) | 48 (11%) | ||
| Thalidomide +- corticosteroid | 85 (16%) | 106 (24%) | ||
| Bortezomib +- corticosteroid | 132 (25%) | 136 (30%) | ||
| Lenalidomide +- corticosteroid | 107 (21%) | 67 (15%) | ||
| Sensitivity to initial therapy# | 491 (95%) | 426 (95%) | 0.85 | |
| Overall cycles of chemotherapy | ||||
| N evaluable | 440 | 402 | ||
| Median (range) | 4 (1–42) | 4 (1–20) | 0.001 | |
| Prior radiation therapy | 110 (21%) | 101 (22%) | 0.63 | |
| Response to initial therapy# | 0.05 | |||
| CR | 84 (16%) | 48 (11%) | ||
| PR/VGPR | 407 (78%) | 378 (84%) | ||
| MR/NR/SD | 28 (5%) | 23 (4%) | ||
| Mobilization cytotoxic chemotherapy | ||||
| Cyclophosphamide | 338 (75%) | |||
| Etoposide | 55 (12%) | |||
| Cyclophosphamide + etoposide | 21 (5%) | |||
| VDT-PACE/similar | 35 (8%) | |||
| Year of transplant | 0.03 | |||
| 2007–2008 | 289 (56%) | 272 (61%) | ||
| 2009–2010 | 105 (20%) | 100 (22%) | ||
| 2011–2012 | 125 (24%) | 77 (17%) | ||
| Time from diagnosis to HCT | <0.001 | |||
| <6 months | 221 (43%) | 140 (31%) | ||
| 6–12 months | 298 (57%) | 309 (69%) | ||
| Melphalan dose for conditioning therapy | 0.40 | |||
| 140–180 mg/m2 | 71 (14%) | 70 (16%) | ||
| >180 mg/m2 | 448 (86%) | 379 (84%) | ||
| Number of transplants† | 0.02 | |||
| Single | 417 (80%) | 331 (74%) | ||
| Planned second auto-HCT | 47 (9%) | 69 (15%) | ||
| Salvage second transplant | 55 (10%) | 49 (11%) | ||
| Maintenance therapy | 0.29 | |||
| None | 321 (62%) | 273 (61%) | ||
| Thalidomide/lenalidomide +- corticosteroids | 147 (28%) | 134 (30%) | ||
| Thalidomide/lenalidomide + bortezomib +- corticosteroids | 32 (6%) | 30 (7%) | ||
| Bortezomib +- corticosteroids | 16 (3%) | 11 (2%) | ||
| Others | 3 (<1%) | 1 (<1%) | ||
*
Durie-Salmon or International Staging System.
**
Excludes cytotoxic chemotherapy administered for mobilization.
#
Assessed prior to mobilization.
†
Analysis is for first transplant only